BMS Report Results of Opdivo + Radiation in P-III CheckMate -498 Study in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

 BMS Report Results of Opdivo + Radiation in P-III CheckMate -498 Study in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

BMS Report Results of Opdivo + Radiation in P-III CheckMate -498 Study in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

Shots:

  • The P-III CheckMate -498 study involves assessing of Opdivo (nivolumab) + radiation vs temozolomide + radiation in patients with newly diagnosed O6- MGMT-unmethylated GBM
  • The P-III CheckMate -498 (NCT02617589) study demonstrated that it did not meet its 1EPs i.e, OS and is safe for solid tumors
  • Opdivo is PD-1 immune checkpoint inhibitor and is approved as a monothx. as well as combination therapy with Yervoy in the US & EU, currently evaluated in P-III CheckMate -548 (NCT02667587) study assessing Opdivo with SOC, radiation & temozolomide

Click here to read full press release/ article | Ref: BMS | Image: Dawson Design

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post